&w=3840&q=100)
Dividend, stock split: Asian Paints, Indian Bank & 3 others to go ex-date
Dividend stocks: Asian Paints, Indian Bank and 3 others will be in focus today as they will trade ex-date on Tuesday, June 10, 2025. In the light of recent announcements regarding corporate action such as dividends, bonus issues, and rights issues, drawing attention from investors. It should be noted that the record date and ex-date for the mentioned stocks are the same.
Shares trading ex-date for final dividend
Asian Paints has declared a final dividend of ₹20.55 per share, Indian Bank ₹16.25, Johnson Controls-Hitachi Air Conditioning India ₹15, and Tata Investment Corporation ₹27 per share, according to corporate action data on BSE.
A final dividend is the amount given by a company to its shareholders after the end of its financial year, based on its full-year profits, and approved by shareholders at the Annual General Meeting (AGM).
Catch Stock Market Updates Today LIVE
Stock split
Apart from that, Vesuvius India will trade ex-date for its stock split of 1:10 ratio. The shareholders will receive 10 equity shares of ₹1 each, fully paid-up, for 1 equity share of ₹10 each, fully paid-up, held by them as on the "record date", upon subdivision/split.
The ex-date (or ex-split date) is the date on or after which a stock trades without the value adjustment for a stock split.
The ex-date marks the day a stock starts trading without the eligibility for dividends, bonus shares, stock splits, or rights issues. This means that investors who purchase the stock on or after the ex-date will not be entitled to these benefits. To be eligible, an investor must hold the stock before the ex-date. However, the final list of beneficiaries for dividends, stock splits, or rights issues is prepared by the company based on shareholders recorded at the close of the record date.
Will investors be eligible to receive dividends, stock splits, or bonus shares if they purchase shares on the ex-date or record date?
No, they won't be eligible for dividends, stock splits, or bonus shares if they buy the stock on the ex-date or record date. To qualify, one must purchase the shares at least one trading day before the ex-date, due to the T+1 settlement cycle in India.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
25 minutes ago
- News18
Reliance Power Soars 11%, Up 174% In A Year – Will The Rally Sustain?
Last Updated: Reliance Power Share Price: Shares of Reliance Power surged on Tuesday, hitting a fresh 10-year high RPower Share Price: Shares of Reliance Power surged on Tuesday, hitting a fresh 10-year high of Rs 71.35, as they rallied 11 per cent on the BSE in intra-day trade amid heavy volumes. At this price, the stock has soared nearly 68 per cent so far in 2025 and 174 per cent over the past year. In June alone, it has gained more than 20 per cent following a 45 per cent surge in May. The recent momentum in this power stock has been driven by its robust Q4 earnings and a positive outlook. For the March 2025 quarter (Q4FY25), Reliance Power reported a consolidated profit of Rs 125.57 crore, reversing a loss of Rs 397.56 crore in the same period last year (Q4FY24). However, consolidated revenue from operations dipped slightly by nearly 1 per cent to Rs 1,978.01 crore from Rs 1,996.65 crore a year earlier. Meanwhile, Reliance Power's subsidiary, Reliance NU Energies Private Limited, on May 28 received a letter of award (LOA) from SJVN Limited—a Navratna Central Public Sector Enterprise—for a 350 MW inter-state transmission system (ISTS)-connected solar power project, along with a 175 MW/700 MWh battery energy storage system (BESS). Reliance Power growth opportunities According to the National Electricity Plan, India plans to add around 80 gigawatts (GW) of new coal-based thermal power capacity by 2031–32 to meet growing electricity demand. In its FY24 annual report, Reliance Power highlighted that this renewed focus presents growth prospects for thermal power players. Rising electrification, higher per-capita power consumption, and the adoption of electric vehicles (EVs) are expected to drive demand. India also aims to achieve 500 GW of non-fossil capacity by 2030 as part of its energy transition. 'In the near term, prices may continue to rise, but given the overbought conditions, buying on dips would be ideal. Rs 56-57 appears to be strong support, while Rs 72 is seen as resistance," Bhosale said. Further, Riyank Arora, Technical Analyst at Mehta Equities, observed that Reliance Power share price is showing signs of profit-booking after the recent rally, with major resistance at Rs 65. 'Reliance Power has seen a significant run-up, and the current pause suggests a short-term consolidation or mild correction. If it fails to break above Rs 65, we may see selling pressure pushing it back towards the Rs 58–59 support zone. While momentum remains positive, traders should be cautious near resistance. Fresh entry is only recommended on a decisive breakout above Rs 65 with strong volume," Arora explained. Disclaimer:Disclaimer: The views and investment tips by experts in this report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decisions.
&w=3840&q=100)
Business Standard
27 minutes ago
- Business Standard
Glenmark Pharma rises 2% as company to launch blood cancer treatment drug
Glenmark Pharma share price rose 1.7 per cent in trade on Tuesday, June 10, 2025, logging an intraday high at ₹1,626.6 per share on BSE. At 10:30 AM, Glenmark Pharma shares were trading 1.56 per cent higher at ₹1,623.35 per share on the BSE. In comparison, the BSE Sensex was up 0.05 per cent at 82,482.52. The company's market capitalisation stood at ₹45,811.07 crore. Its 52-week high was at ₹1,830.05 per share and 52-week low was at ₹1,176 per share. In the past one year, Glenmark shares have gained 33 per cent as compared to Sensex's rise of around 8 per cent. What is boosting rally in Glenmark Pharma shares? The stock gained after the company announced the upcoming launch of zanubrutinib, under the brand name Brukinsa in India. Brukinsa, developed by global oncology company BeOne Medicines (formerly BeiGene), is an orally available Bruton's tyrosine kinase (BTK) inhibitor designed to treat multiple types of B-cell blood cancers. It is the first and only BTK inhibitor approved in India for five types of B-cell malignancies. According to the filing, Brukinsa has already been approved in more than 70 countries, with clinical efficacy demonstrated through trials such as ALPINE, ASPEN and SEQUOIA. Its entry into the Indian market addresses a critical need for new and effective blood cancer treatments. The drug offers a unique pharmacological profile with high response rates and durable disease control across multiple B-cell malignancies. It allows a flexible dosing schedule—once or twice daily—tailored to patient needs. In the ALPINE trial for relapsed or refractory chronic lymphocytic leukaemia (CLL), Brukinsa showed a lower incidence of serious cardiac side effects compared to ibrutinib, a widely used targeted therapy. Fewer patients discontinued Brukinsa due to heart-related complications. About Glenmark Pharmaceuticals Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. About BeOne Medicines BeOne Medicines, formerly known as BeiGene, is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.
Business Standard
28 minutes ago
- Business Standard
RITES bags LoA from Guyana's Public Works Ministry for $2.9 million project
RITES said that it has received letter of acceptance (LOA) for a coastal road project from the Ministry of Public Works, the Co-operative Republic of Guyana worth $2.908 million. Under the contract, RITES will provide construction supervision for the extension of the East Bank-East Coast Road Project Phase 2 (Eccles to Providence), which also includes additional work for an existing assignment. The project is slated for completion within 18 months of construction supervision, followed by a 12-month defects liability period. RITES, a Miniratna (Category-I) Schedule 'A' public sector enterprise, is a leading player in the transport consultancy and engineering sector in India, having diversified services and geographical reach. As of 31 March 2025, the Government of India held 72.20% stake in the company. The company's consolidated net profit rose 5.24% to Rs 132.71 crore despite a 4.32% decline in revenue to Rs 615.43 crore in Q4 FY25 as compared with Q4 FY24. The scrip rose 0.94% to currently trade at Rs 305.10 on the BSE.
